中国乳腺癌新辅助治疗专家组 . 中国乳腺癌新辅助治疗专家共识(2019年版) [J ] . 中国癌症杂志 , 2019 , 29 ( 5 ): 390 - 400 .

China Breast Cancer Neoadjuvant Therapy Expert Group . Expert consensus on neoadjuvant therapy for breast cancer in China (2019 edition) [J ] . China Oncol , 2019 , 29 ( 5 ): 390 - 400 .

KORDE L A , SOMERFIELD M R , CAREY L A , et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline [J ] . J Clin Oncol , 2021 , 39 ( 13 ): 1485 - 1505 . DOI: 10.1200/JCO.20.03399 http://doi.org/10.1200/JCO.20.03399 https://ascopubs.org/doi/10.1200/JCO.20.03399 https://ascopubs.org/doi/10.1200/JCO.20.03399

BURSTEIN H J , CURIGLIANO G , THÜRLIMANN B , et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 [J ] . Ann Oncol , 2021 , 32 ( 10 ): 1216 - 1235 . DOI: 10.1016/j.annonc.2021.06.023 http://doi.org/10.1016/j.annonc.2021.06.023 https://linkinghub.elsevier.com/retrieve/pii/S0923753421021049 https://linkinghub.elsevier.com/retrieve/pii/S0923753421021049

中国抗癌协会乳腺癌专业委员会 . 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J ] . 中国癌症杂志 , 2021 , 31 ( 10 ): 954 - 1040 .

The Society of Breast Cancer China Anti-Cancer Association . Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2021 edition) [J ] . China Oncol , 2021 , 31 ( 10 ): 954 - 1040 .

BOUGHEY J C , SUMAN V J , MITTENDORF E A , et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial [J ] . JAMA , 2013 , 310 ( 14 ): 1455 - 1461 . DOI: 10.1001/jama.2013.278932 http://doi.org/10.1001/jama.2013.278932 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2013.278932 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2013.278932

BRACKSTONE M , BALDASSARRE F G , PERERA F E , et al. Management of the axilla in early-stage breast cancer: Ontario health (cancer care Ontario) and ASCO guideline [J ] . J Clin Oncol , 2021 , 39 ( 27 ): 3056 - 3082 . DOI: 10.1200/JCO.21.00934 http://doi.org/10.1200/JCO.21.00934 https://ascopubs.org/doi/10.1200/JCO.21.00934 https://ascopubs.org/doi/10.1200/JCO.21.00934

JUNG S Y , HAN J H , PARK S J , et al. The sentinel lymph node biopsy using indocyanine green fluorescence plus radioisotope method compared with the radioisotope-only method for breast cancer patients after neoadjuvant chemotherapy: a prospective, randomized, open-label, single-center phase 2 trial [J ] . Ann Surg Oncol , 2019 , 26 ( 8 ): 2409 - 2416 . DOI: 10.1245/s10434-019-07400-0 http://doi.org/10.1245/s10434-019-07400-0 https://doi.org/10.1245/s10434-019-07400-0 https://doi.org/10.1245/s10434-019-07400-0

MAMTANI A , BARRIO A V , KING T A , et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study [J ] . Ann Surg Oncol , 2016 , 23 ( 11 ): 3467 - 3474 . DOI: 10.1245/s10434-016-5246-8 http://doi.org/10.1245/s10434-016-5246-8 http://link.springer.com/10.1245/s10434-016-5246-8 http://link.springer.com/10.1245/s10434-016-5246-8

《乳腺癌新辅助治疗的病理诊断专家共识2020版》编写组 . 乳腺癌新辅助治疗的病理诊断专家共识(2020版) [J ] . 中华病理学杂志 , 2020 , 49 ( 4 ): 296 - 304 .

Writing Group of Expert Panel Consensus on Pathological Diagnosis of Breast Cancer with Neoadjuvant Therapy, the 2020 Version . Expert panel consensus on pathological diagnosis of breast cancer with neoadjuvant therapy, the 2020 version [J ] . Chin J Pathol , 2020 , 49 ( 4 ): 296 - 304 .

EL-DIDI M H , MONEER M M , KHALED H M , et al. Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management [J ] . Surg Today , 2000 , 30 ( 3 ): 249 - 254 . DOI: 10.1007/s005950050054 http://doi.org/10.1007/s005950050054 http://link.springer.com/10.1007/s005950050054 http://link.springer.com/10.1007/s005950050054

HARBECK N , GLUZ O , CHRISTGEN M , et al. De-escalation strategies in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (BC): final analysis of the west German study group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2 - and hormone receptor-positive phase & #x02161; randomized trial-efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET [J ] . J Clin Oncol , 2017 , 35 ( 26 ): 3046 - 3054 . DOI: 10.1200/JCO.2016.71.9815 http://doi.org/10.1200/JCO.2016.71.9815 https://ascopubs.org/doi/10.1200/JCO.2016.71.9815 https://ascopubs.org/doi/10.1200/JCO.2016.71.9815

PÉREZ-GARCÍA J M , GEBHART G , RUIZ BORREGO M , et al. Chemotherapy de-escalation using an 18 F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial [J ] . Lancet Oncol , 2021 , 22 ( 6 ): 858 - 871 . DOI: 10.1016/S1470-2045(21)00122-4 http://doi.org/10.1016/S1470-2045(21)00122-4 https://linkinghub.elsevier.com/retrieve/pii/S1470204521001224 https://linkinghub.elsevier.com/retrieve/pii/S1470204521001224

LOIBL S , UNTCH M , BURCHARDI N , et al. A randomised phase Ⅱ study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study [J ] . Ann Oncol , 2019 , 30 ( 8 ): 1279 - 1288 . DOI: 10.1093/annonc/mdz158 http://doi.org/10.1093/annonc/mdz158 https://linkinghub.elsevier.com/retrieve/pii/S0923753419312785 https://linkinghub.elsevier.com/retrieve/pii/S0923753419312785

MITTENDORF E A , ZHANG H , BARRIOS C H , et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial [J ] . Lancet , 2020 , 396 ( 10257 ): 1090 - 1100 . DOI: 10.1016/S0140-6736(20)31953-X http://doi.org/10.1016/S0140-6736(20)31953-X https://linkinghub.elsevier.com/retrieve/pii/S014067362031953X https://linkinghub.elsevier.com/retrieve/pii/S014067362031953X

SCHMID P , CORTES J , PUSZTAI L , et al. Pembrolizumab for early triple-negative breast cancer [J ] . N Engl J Med , 2020 , 382 ( 9 ): 810 - 821 . DOI: 10.1056/NEJMoa1910549 http://doi.org/10.1056/NEJMoa1910549 http://www.nejm.org/doi/10.1056/NEJMoa1910549 http://www.nejm.org/doi/10.1056/NEJMoa1910549

POGGIO F , BRUZZONE M , CEPPI M , et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis [J ] . Ann Oncol , 2018 , 29 ( 7 ): 1497 - 1508 . DOI: 10.1093/annonc/mdy127 http://doi.org/10.1093/annonc/mdy127 https://linkinghub.elsevier.com/retrieve/pii/S0923753419320988 https://linkinghub.elsevier.com/retrieve/pii/S0923753419320988

ELLIS M J , SUMAN V J , HOOG J , et al. Ki-67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology group Z1031 trial (alliance) [J ] . J Clin Oncol , 2017 , 35 ( 10 ): 1061 - 1069 . DOI: 10.1200/JCO.2016.69.4406 http://doi.org/10.1200/JCO.2016.69.4406 https://ascopubs.org/doi/10.1200/JCO.2016.69.4406 https://ascopubs.org/doi/10.1200/JCO.2016.69.4406

NITZ U , GLUZ O , KREIPE H H , et al. The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer [J ] . Ther Adv Med Oncol , 2020 , 12 : 1758835920973130 .

SCHNEEWEISS A , CHIA S , HICKISH T , et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA) [J ] . Ann Oncol , 2013 , 24 ( 9 ): 2278 - 2284 . DOI: 10.1093/annonc/mdt182 http://doi.org/10.1093/annonc/mdt182 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369297 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369297

HURVITZ S A , MARTIN M , JUNG K H , et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase Ⅲ KRISTINE study [J ] . J Clin Oncol , 2019 , 37 ( 25 ): 2206 - 2216 . DOI: 10.1200/JCO.19.00882 http://doi.org/10.1200/JCO.19.00882 https://ascopubs.org/doi/10.1200/JCO.19.00882 https://ascopubs.org/doi/10.1200/JCO.19.00882

VAN RAMSHORST M S , VAN DER VOORT A , VAN WERKHOVEN E D , et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial [J ] . Lancet Oncol , 2018 , 19 ( 12 ): 1630 - 1640 . DOI: 10.1016/S1470-2045(18)30570-9 http://doi.org/10.1016/S1470-2045(18)30570-9 https://linkinghub.elsevier.com/retrieve/pii/S1470204518305709 https://linkinghub.elsevier.com/retrieve/pii/S1470204518305709

NCCN Clinical Practice Guidelines in Oncology-Breast Cancer (Version 8 2021) [M ] . 2021 .

MASUDA N , LEE S J , OHTANI S , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy [J ] . N Engl J Med , 2017 , 376 ( 22 ): 2147 - 2159 . DOI: 10.1056/NEJMoa1612645 http://doi.org/10.1056/NEJMoa1612645 http://www.nejm.org/doi/10.1056/NEJMoa1612645 http://www.nejm.org/doi/10.1056/NEJMoa1612645

VON MINCKWITZ G , HUANG C S , MANO M S , et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer [J ] . N Engl J Med , 2019 , 380 ( 7 ): 617 - 628 . DOI: 10.1056/NEJMoa1814017 http://doi.org/10.1056/NEJMoa1814017 http://www.nejm.org/doi/10.1056/NEJMoa1814017 http://www.nejm.org/doi/10.1056/NEJMoa1814017

VON MINCKWITZ G , BLOHMER J U , COSTA S D , et al. Response-guided neoadjuvant chemotherapy for breast cancer [J ] . J Clin Oncol , 2013 , 31 ( 29 ): 3623 - 3630 . DOI: 10.1200/JCO.2012.45.0940 http://doi.org/10.1200/JCO.2012.45.0940 http://ascopubs.org/doi/10.1200/JCO.2012.45.0940 http://ascopubs.org/doi/10.1200/JCO.2012.45.0940

CROSHAW R , SHAPIRO-WRIGHT H , SVENSSON E , et al. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients [J ] . Ann Surg Oncol , 2011 , 18 ( 11 ): 3160 - 3163 . DOI: 10.1245/s10434-011-1919-5 http://doi.org/10.1245/s10434-011-1919-5 http://link.springer.com/10.1245/s10434-011-1919-5 http://link.springer.com/10.1245/s10434-011-1919-5

GIANNI L , EIERMANN W , SEMIGLAZOV V , et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort [J ] . Lancet , 2010 , 375 ( 9712 ): 377 - 384 . DOI: 10.1016/S0140-6736(09)61964-4 http://doi.org/10.1016/S0140-6736(09)61964-4 https://linkinghub.elsevier.com/retrieve/pii/S0140673609619644 https://linkinghub.elsevier.com/retrieve/pii/S0140673609619644

GIANNI L , PIENKOWSKI T , IM Y H , et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J ] . Lancet Oncol , 2016 , 17 ( 6 ): 791 - 800 . DOI: 10.1016/S1470-2045(16)00163-7 http://doi.org/10.1016/S1470-2045(16)00163-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204516001637 https://linkinghub.elsevier.com/retrieve/pii/S1470204516001637

JOHNSTON S R D , HARBECK N , HEGG R , et al. Abemaciclib combined with endocrine therapy for the adjuvant tre atment of HR + , HER2 - , node-positive, high-risk, early breast cancer (monarchE) [J ] . J Clin Oncol , 2020 , 38 ( 34 ): 3987 - 3998 . DOI: 10.1200/JCO.20.02514 http://doi.org/10.1200/JCO.20.02514 https://ascopubs.org/doi/10.1200/JCO.20.02514 https://ascopubs.org/doi/10.1200/JCO.20.02514

MAYER I A , ZHAO F M , ARTEAGA C L , et al. Randomized phase Ⅲ postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131 [J ] . J Clin Oncol , 2021 , 39 ( 23 ): 2539 - 2551 . DOI: 10.1200/JCO.21.00976 http://doi.org/10.1200/JCO.21.00976 https://ascopubs.org/doi/10.1200/JCO.21.00976 https://ascopubs.org/doi/10.1200/JCO.21.00976

LOIBL S , MARMÉ F , MARTIN M , et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial [J ] . J Clin Oncol , 2021 , 39 ( 14 ): 1518 - 1530 . DOI: 10.1200/JCO.20.03639 http://doi.org/10.1200/JCO.20.03639 https://ascopubs.org/doi/10.1200/JCO.20.03639 https://ascopubs.org/doi/10.1200/JCO.20.03639